Daniëlle C.H. Jacobs

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

Michel de Weers, Yu‐Tzu Tai, Michael S. van der Veer et al. · The Journal of Immunology · 2010 · 1K citations · Full text

Medicine, Oncology, Pharmacology +17

The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers

Miranda M.C. van der Lee, Patrick G. Groothuis, Ruud Ubink et al. · Molecular Cancer Therapeutics · 2015 · 215 citations

Pharmacy, Oncology, Pharmacology +16

Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform

Wim H.A. Dokter, Ruud Ubink, Miranda van der Lee et al. · Molecular Cancer Therapeutics · 2014 · 163 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Vδ2-Jα rearrangements are frequent in precursor-B–acute lymphoblastic leukemia but rare in normal lymphoid cells

Tomasz Szczepański, Vincent H. J. van der Velden, Patricia G. Hoogeveen et al. · Blood · 2003 · 73 citations · Full text

Medicine, Hematology, Oncology +13

Daratumumab, a Novel Potent Human Anti-CD38 Monoclonal Antibody, Induces Significant Killing of Human Multiple Myeloma Cells: Therapeutic Implication.

Yu‐Tzu Tai, Michel de Weers, Xianfeng Li et al. · Blood · 2009 · 13 citations

Medicine, Oncology, Pharmacology +16